RJFSA
PVLA

Raymond James Financial Services Advisors’s Palvella Therapeutics PVLA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-325
Closed -$59K – 2917
2020
Q1 		$59K Buy
+325
New +$81.9K ﹤0.01% 2300

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial Services Advisors's PVLA Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 325 shares — an estimated $59K sold.

Raymond James Financial Services Advisors first reported a position in PVLA in Q1 2020 and held it in 1 quarter. The position peaked at $59K in Q1 2020. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 325 Palvella Therapeutics shares in Q2 2020, an estimated $59K.
  • Raymond James Financial Services Advisors first reported a position in Palvella Therapeutics in Q1 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Palvella Therapeutics position peaked at $59K in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.